Sale!
, , , , , , , , , , , ,

VLS Retatrutide Pen

Price range: £150.00 through £220.00

Retatrutide is a next-generation triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. This VLS pre-filled pen offers precise, convenient administration for metabolic and weight management research.


/* TPS Product Description Styles */
.tps-product-desc {
font-family: inherit;
color: #333;
line-height: 1.6;
}

/* Janoshik Verification Box */
.tps-janoshik-box {
background: linear-gradient(135deg, #f0fdf4 0%, #dcfce7 100%);
border: 2px solid #22c55e;
border-radius: 12px;
padding: 20px;
margin-bottom: 28px;
display: flex;
flex-wrap: wrap;
align-items: center;
gap: 16px;
}

.tps-janoshik-badge {
display: flex;
align-items: center;
gap: 10px;
flex: 1;
min-width: 200px;
}

.tps-janoshik-icon {
width: 48px;
height: 48px;
background: #22c55e;
border-radius: 50%;
display: flex;
align-items: center;
justify-content: center;
flex-shrink: 0;
}

.tps-janoshik-icon svg {
width: 28px;
height: 28px;
stroke: white;
}

.tps-janoshik-text h4 {
margin: 0 0 2px 0;
font-size: 16px;
font-weight: 700;
color: #166534;
}

.tps-janoshik-text p {
margin: 0;
font-size: 14px;
color: #15803d;
}

.tps-janoshik-stats {
display: flex;
gap: 20px;
flex-wrap: wrap;
}

.tps-janoshik-stat {
text-align: center;
padding: 8px 16px;
background: white;
border-radius: 8px;
box-shadow: 0 1px 3px rgba(0,0,0,0.1);
}

.tps-janoshik-stat .value {
font-size: 20px;
font-weight: 800;
color: #166534;
display: block;
}

.tps-janoshik-stat .label {
font-size: 11px;
text-transform: uppercase;
letter-spacing: 0.5px;
color: #6b7280;
}

.tps-janoshik-verify {
width: 100%;
margin-top: 8px;
padding-top: 12px;
border-top: 1px solid rgba(34, 197, 94, 0.3);
font-size: 12px;
color: #6b7280;
}

.tps-janoshik-verify a {
color: #166534;
font-weight: 600;
text-decoration: none;
}

.tps-janoshik-verify a:hover {
text-decoration: underline;
}

/* Section Headers */
.tps-product-desc h2 {
font-size: 22px;
font-weight: 700;
color: #1a1a1a;
margin: 32px 0 16px 0;
padding-bottom: 8px;
border-bottom: 3px solid #45aad3;
display: inline-block;
}

.tps-product-desc h3 {
font-size: 17px;
font-weight: 600;
color: #333;
margin: 24px 0 12px 0;
}

/* Intro Paragraph */
.tps-intro {
font-size: 16px;
color: #444;
margin-bottom: 24px;
padding: 16px;
background: #f8fafc;
border-left: 4px solid #45aad3;
border-radius: 0 8px 8px 0;
}

/* Specs Grid */
.tps-specs-grid {
display: grid;
grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
gap: 12px;
margin: 20px 0 28px 0;
}

.tps-spec-item {
background: #f8fafc;
border: 1px solid #e2e8f0;
border-radius: 10px;
padding: 14px;
text-align: center;
transition: all 0.2s ease;
}

.tps-spec-item:hover {
border-color: #45aad3;
box-shadow: 0 4px 12px rgba(69, 170, 211, 0.15);
}

.tps-spec-item .spec-label {
font-size: 11px;
text-transform: uppercase;
letter-spacing: 0.5px;
color: #64748b;
margin-bottom: 4px;
}

.tps-spec-item .spec-value {
font-size: 15px;
font-weight: 700;
color: #1a1a1a;
}

/* Benefits List */
.tps-benefits {
list-style: none;
padding: 0;
margin: 16px 0;
}

.tps-benefits li {
position: relative;
padding: 10px 0 10px 32px;
border-bottom: 1px solid #f1f5f9;
font-size: 15px;
}

.tps-benefits li:last-child {
border-bottom: none;
}

.tps-benefits li::before {
content: ”;
position: absolute;
left: 0;
top: 50%;
transform: translateY(-50%);
width: 20px;
height: 20px;
background: #45aad3;
border-radius: 50%;
background-image: url(“data:image/svg+xml,%3Csvg xmlns=’http://www.w3.org/2000/svg’ viewBox=’0 0 24 24′ fill=’none’ stroke=’white’ stroke-width=’3’%3E%3Cpath d=’M5 12l5 5L20 7’/%3E%3C/svg%3E”);
background-size: 12px;
background-position: center;
background-repeat: no-repeat;
}

/* Brand Box – VLS Orange theme */
.tps-brand-box {
display: flex;
align-items: center;
justify-content: center;
gap: 12px;
padding: 14px 18px;
background: linear-gradient(135deg, #fff7ed 0%, #ffedd5 100%);
border: 1px solid #f97316;
border-radius: 8px;
margin: 28px 0;
}

.tps-brand-box span {
font-size: 14px;
color: #9a3412;
font-weight: 500;
}

.tps-brand-box strong {
color: #c2410c;
font-weight: 700;
}

/* Dosage Info */
.tps-dosage-box {
background: #fffbeb;
border: 1px solid #fcd34d;
border-radius: 10px;
padding: 16px 20px;
margin: 20px 0;
}

.tps-dosage-box h4 {
margin: 0 0 8px 0;
font-size: 14px;
font-weight: 700;
color: #92400e;
display: flex;
align-items: center;
gap: 8px;
}

.tps-dosage-box p {
margin: 0;
font-size: 14px;
color: #78350f;
}

/* Mobile Optimizations */
@media (max-width: 600px) {
.tps-janoshik-box {
padding: 16px;
}

.tps-janoshik-stats {
width: 100%;
justify-content: space-around;
}

.tps-specs-grid {
grid-template-columns: repeat(2, 1fr);
}

.tps-brand-box {
padding: 12px 14px;
}

.tps-product-desc h2 {
font-size: 19px;
}
}

Janoshik Lab Verified

Independent third-party testing

99.49%
Purity
6.52mg/ml
Content
🔗 Verify at janoshik.com/verify using key: 2HPDNTUWCH9K | Tested: Sept 2025

VLS Retatrutide Pen is a next-generation triple agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. This pre-filled Retatrutide injection pen offers convenient, precise administration for research into weight management, metabolic health, and appetite regulation. Available for UK delivery with fast dispatch.

Retatrutide Pen Specifications

Peptide
Retatrutide
Type
Triple Agonist
Format
Pre-filled Pen
Concentration
6.66mg/ml
Purity
99.49%
Brand
VLS

VLS Retatrutide 20mg Pre-filled Injection Pen

Retatrutide Research Benefits

How Retatrutide Works

Retatrutide is a novel triple agonist peptide that activates three key receptors involved in metabolic regulation: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This multi-receptor approach differentiates it from single or dual agonists like semaglutide or tirzepatide.

By targeting all three pathways, Retatrutide research has shown potential for enhanced effects on appetite suppression, glucose metabolism, and energy expenditure. Clinical trials have demonstrated significant interest in its application for obesity and type 2 diabetes research.

Retatrutide vs Tirzepatide vs Semaglutide

While Semaglutide targets only GLP-1 and Tirzepatide targets GLP-1 and GIP, Retatrutide adds glucagon receptor activation for a triple-action approach. Early research suggests this may offer advantages in metabolic studies, making Retatrutide pens increasingly sought after for laboratory investigation.

⚠️ FOR LABORATORY RESEARCH USE ONLY

NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE

Safety Classification:
– For use by qualified research personnel only
– Keep detailed records of usage and storage as per UK research regulations

Legal Notice: This product is exclusively intended for in vitro laboratory research conducted in controlled environments by qualified research staff. It is not for pharmaceutical, domestic, or any other applications. The purchaser accepts that acquiring and using this material is governed by all relevant UK regulations concerning research chemicals.

Dose

20mg, 40mg

Shopping Cart